Chemfab Alkalis Limited Declares Q3 FY26 Unaudited Financial Results
Chemfab Alkalis Limited reported un-audited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The company experienced a net loss of ₹103.80 lakhs on a standalone basis and ₹479.33 lakhs on a consolidated basis for the quarter. For the nine months, standalone net profit was ₹594.62 lakhs, while consolidated net loss was ₹142.30 lakhs. 10,000 equity shares were allotted under ESOPs.
The financial results show losses for the quarter and a mixed performance for the nine-month period (profit standalone, loss consolidated). While not a severe crisis, the losses warrant attention and could impact investor sentiment.
The company reported losses on a standalone basis for the quarter and on a consolidated basis for both the quarter and nine months ended December 31, 2025, which indicates a negative financial performance.
Chemfab Alkalis Limited announced its Un-Audited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. The Board meeting, held on January 28, 2026, commenced at 2:00 PM and concluded at 5:00 PM, approving the financial results as recommended by the Audit Committee.
The standalone results for the quarter ended December 31, 2025, show a total income of ₹6,371.32 lakhs, with total expenses amounting to ₹6,509.65 lakhs, resulting in a net loss after tax of ₹103.80 lakhs. For the nine months ended December 31, 2025, total income was ₹22,410.41 lakhs and total expenses were ₹21,568.04 lakhs, leading to a net profit after tax of ₹594.62 lakhs.
On a consolidated basis for the quarter ended December 31, 2025, the company reported a total income of ₹7,091.21 lakhs and total expenses of ₹7,570.54 lakhs, resulting in a net loss after tax of ₹479.33 lakhs. For the nine months ended December 31, 2025, consolidated total income stood at ₹24,213.42 lakhs with total expenses of ₹24,355.92 lakhs, yielding a net loss after tax of ₹142.30 lakhs.
During the nine months ended December 31, 2025, the company allotted 10,000 equity shares under its Employee Stock Option Scheme 'CAESOS 2020'. The company also noted that the incremental impact of the new labour codes, effective November 21, 2025, is immaterial based on current information.
What to do with a filing like this
Chemfab Alkalis Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Chemfab Alkalis Limited. Read the original for the full detail.